Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
Kivu Bioscience Inc.
Bayer
Karyopharm Therapeutics Inc
Kaiser Permanente
Children's Oncology Group
AstraZeneca
Institute of Cancer Research, United Kingdom
SEED Therapeutics, Inc.
MacroGenics
UNC Lineberger Comprehensive Cancer Center
Solve Therapeutics
University of Nebraska
Adela, Inc
National Institutes of Health Clinical Center (CC)
Tanabe Pharma America, Inc.
Blueprint Medicines Corporation
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Leap Therapeutics, Inc.
Leap Therapeutics, Inc.
National Cancer Institute (NCI)
PharmaMar
NextPoint Therapeutics, Inc.
Tempus AI
Region Skane
University of South Florida
Northwestern University
Agenus Inc.
Memorial Sloan Kettering Cancer Center
Brown University
Xencor, Inc.
Prelude Therapeutics
University Hospital, Gasthuisberg
Innolake Biopharm
Celon Pharma SA
Corvus Pharmaceuticals, Inc.
pharmaand GmbH
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
University of Manchester
NKGen Biotech, Inc.
CureOne
Merrimack Pharmaceuticals
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota